1
|
Jeong JH, Kim JS, Choi YR, Shin DH, Kang JH, Kim DW, Park YS, Park CW. Preparation and Evaluation of Inhalable Microparticles with Improved Aerodynamic Performance and Dispersibility Using L-Leucine and Hot-Melt Extrusion. Pharmaceutics 2024; 16:784. [PMID: 38931905 PMCID: PMC11206964 DOI: 10.3390/pharmaceutics16060784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2024] [Revised: 06/03/2024] [Accepted: 06/04/2024] [Indexed: 06/28/2024] Open
Abstract
Dry-powder inhalers (DPIs) are valued for their stability but formulating them is challenging due to powder aggregation and limited flowability, which affects drug delivery and uniformity. In this study, the incorporation of L-leucine (LEU) into hot-melt extrusion (HME) was proposed to enhance dispersibility while simultaneously maintaining the high aerodynamic performance of inhalable microparticles. This study explored using LEU in HME to improve dispersibility and maintain the high aerodynamic performance of inhalable microparticles. Formulations with crystalline itraconazole (ITZ) and LEU were made via co-jet milling and HME followed by jet milling. The LEU ratio varied, comparing solubility, homogenization, and aerodynamic performance enhancements. In HME, ITZ solubility increased, and crystallinity decreased. Higher LEU ratios in HME formulations reduced the contact angle, enhancing mass median aerodynamic diameter (MMAD) size and aerodynamic performance synergistically. Achieving a maximum extra fine particle fraction of 33.68 ± 1.31% enabled stable deep lung delivery. This study shows that HME combined with LEU effectively produces inhalable particles, which is promising for improved drug dispersion and delivery.
Collapse
Affiliation(s)
- Jin-Hyuk Jeong
- Department of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea; (J.-H.J.); (J.-S.K.); (Y.-R.C.); (D.H.S.); (J.-H.K.)
| | - Ji-Su Kim
- Department of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea; (J.-H.J.); (J.-S.K.); (Y.-R.C.); (D.H.S.); (J.-H.K.)
| | - Yu-Rim Choi
- Department of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea; (J.-H.J.); (J.-S.K.); (Y.-R.C.); (D.H.S.); (J.-H.K.)
| | - Dae Hwan Shin
- Department of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea; (J.-H.J.); (J.-S.K.); (Y.-R.C.); (D.H.S.); (J.-H.K.)
| | - Ji-Hyun Kang
- Department of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea; (J.-H.J.); (J.-S.K.); (Y.-R.C.); (D.H.S.); (J.-H.K.)
- Institute of New Drug Development and Respiratory Drug Development Research Institute, School of Pharmacy, Jeonbuk National University, Jeonju 54896, Republic of Korea
| | - Dong-Wook Kim
- College of Pharmacy, Wonkwang University, Iksan 54538, Republic of Korea;
| | - Yun-Sang Park
- Research & Development Center, P2K Bio, Cheongju 28160, Republic of Korea;
| | - Chun-Woong Park
- Department of Pharmacy, Chungbuk National University, Cheongju 28644, Republic of Korea; (J.-H.J.); (J.-S.K.); (Y.-R.C.); (D.H.S.); (J.-H.K.)
| |
Collapse
|
2
|
Al-Japairai K, Hamed Almurisi S, Mahmood S, Madheswaran T, Chatterjee B, Sri P, Azra Binti Ahmad Mazlan N, Al Hagbani T, Alheibshy F. Strategies to improve the stability of amorphous solid dispersions in view of the hot melt extrusion (HME) method. Int J Pharm 2023; 647:123536. [PMID: 37865133 DOI: 10.1016/j.ijpharm.2023.123536] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2023] [Revised: 09/24/2023] [Accepted: 10/18/2023] [Indexed: 10/23/2023]
Abstract
Oral administration of drugs is preferred over other routes for several reasons: it is non-invasive, easy to administer, and easy to store. However, drug formulation for oral administration is often hindered by the drug's poor solubility, which limits its bioavailability and reduces its commercial value. As a solution, amorphous solid dispersion (ASD) was introduced as a drug formulation method that improves drug solubility by changing the molecular structure of the drugs from crystalline to amorphous. The hot melt extrusion (HME) method is emerging in the pharmaceutical industry as an alternative to manufacture ASD. However, despite solving solubility issues, ASD also exposes the drug to a high risk of crystallisation, either during processing or storage. Formulating a successful oral administration drug using ASD requires optimisation of the formulation, polymers, and HME manufacturing processes applied. This review presents some important considerations in ASD formulation, including strategies to improve the stability of the final product using HME to allow more new drugs to be formulated using this method.
Collapse
Affiliation(s)
- Khater Al-Japairai
- Department of Pharmaceutical Engineering, Faculty of Chemical and Process Engineering Technology, Universiti Malaysia Pahang Al-Sultan Abdullah, Gambang 26300, Malaysia.
| | - Samah Hamed Almurisi
- Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia.
| | - Syed Mahmood
- Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Malaya, 50603 Kuala Lumpur, Malaysia.
| | - Thiagarajan Madheswaran
- Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia.
| | - Bappaditya Chatterjee
- Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM's NMIMS, V.L.Mehta Road, Mumbai 400055, India.
| | - Prasanthi Sri
- Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia.
| | | | - Turki Al Hagbani
- Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia.
| | - Fawaz Alheibshy
- Department of Pharmaceutics, College of Pharmacy, University of Ha'il, Ha'il 81442, Saudi Arabia; Department of Pharmaceutics, College of Pharmacy, Aden University, Aden 6075, Yemen.
| |
Collapse
|
3
|
Khalid GM, Billa N. Drug-Eluting Sutures by Hot-Melt Extrusion: Current Trends and Future Potentials. MATERIALS (BASEL, SWITZERLAND) 2023; 16:7245. [PMID: 38005174 PMCID: PMC10672932 DOI: 10.3390/ma16227245] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/08/2023] [Revised: 11/06/2023] [Accepted: 11/16/2023] [Indexed: 11/26/2023]
Abstract
Surgical site infections (SSIs) may result from surgical procedures requiring a secondary administration of drugs at site or systemically in treating the infection. Drug-eluting sutures containing antimicrobial agents symbolise a latent strategy that precludes a secondary drug administration. It also offers the possibility of delivering a myriad of therapeutic agents to a localised wound site to effect analgesia, anti-inflammation, or the deployment of proteins useful for wound healing. Further, the use of biodegradable drug-eluting sutures eliminates the need for implanting foreign material into the wound, which needs to be removed after healing. In this review, we expound on recent trends in the manufacture of drug-eluting sutures with a focus on the hot-melt extrusion (HME) technique. HME provides a solvent-free, continuous one-step manufacturing conduit for drug-eluting sutures, hence, there is no drying step, which can be detrimental to the drug or suture threads and, thus, environmentally friendly. There is the possibility of combining the technology with additive manufacturing platforms to generate personalised drug-loaded implantable devices through prototyping and scalability. The review also highlights key material requirements for fabricating drug-eluting sutures by HME, as well as quality attributes. Finally, a preview of emerging drug-eluting sutures and advocacy for harmonisation of quality assurance by regulatory authorities that permits quality evaluation of novelty sutures is presented.
Collapse
Affiliation(s)
- Garba M. Khalid
- Department of Pharmaceutics, UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK;
- FabRx Ltd., Henwood House, Henwood, Asford TN24 8DH, UK
| | - Nashiru Billa
- Pharmaceutical Sciences Department, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar
| |
Collapse
|
4
|
Liu T, Zhang F. Modelling drug degradation of amorphous solid dispersion during twin-screw extrusion. Eur J Pharm Biopharm 2023; 190:197-205. [PMID: 37524213 DOI: 10.1016/j.ejpb.2023.07.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2023] [Revised: 07/24/2023] [Accepted: 07/28/2023] [Indexed: 08/02/2023]
Abstract
Twin-screw extrusion is one of the major technologies for solid dispersion in the pharmaceutical industry. However, the thermal exposure to the drug during extrusion can easily trigger and exacerbate drug degradation. A conventional method for investigating drug degradation in extrusion is trial-and-error, which can consume much time and material. We propose to model drug degradation kinetics and combine it with thermal history simulation to predict drug degradation. Ritonavir and copovidone were used as a model system of solid dispersion. Hydantoin aminoalchol was the major degradant of RTV in extrudate. In studying the RTV degradation kinetics, only in nitrogen atmosphere, RTV degradation pathway in TGA or DSC was like the degradation pathway in extrusion. The mixing and solubilization of RTV in copovidone also prevented RTV from degrading to oxazolidine derivative. The degradation samples were collected at various temperatures and at different times. The data was fitted into first-order kinetics model to get degradation rates constant at each temperature. The degradation rate constants were fitted into the Arrhenius equation with an activation energy of 159.3 kJ/mol, and a pre-exponential of 1.23 × 1017. An array of extrusion conditions was developed and analyzed via design of experiment (DOE). Relying on the measured melt temperature and residence time after kneading element and die, we simulated the thermal history in the section between kneading element and die. The RTV degradation kinetics in conjunction with simulated thermal history predicted degradation and achieved a 78% regression.
Collapse
Affiliation(s)
- Tongzhou Liu
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, A1920 Austin, TX 78712, USA
| | - Feng Zhang
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, A1920 Austin, TX 78712, USA.
| |
Collapse
|
5
|
Nyamba I, Jennotte O, Sombie CB, Lechanteur A, Sacre PY, Djande A, Semde R, Evrard B. Preformulation study for the selection of a suitable polymer for the development of ellagic acid-based solid dispersion using hot-melt extrusion. Int J Pharm 2023:123088. [PMID: 37257795 DOI: 10.1016/j.ijpharm.2023.123088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2022] [Revised: 05/22/2023] [Accepted: 05/25/2023] [Indexed: 06/02/2023]
Abstract
Ellagic acid is one of the most studied polyphenolic compounds due to its numerous promising therapeutic properties. However, this therapeutic potential remains difficult to exploit owing to its low solubility and low permeability, resulting in low oral bioavailability. In order to allow an effective therapeutic application of EA, it is therefore necessary to develop strategies that sufficiently enhance its solubility, dissolution rate and bioavailability. For this purpose, solid dispersions based on pre-selected polymers such as Eudragit® EPO, Soluplus® and Kollidon® VA 64, with 5% w/w ellagic acid loading were prepared by hot extrusion and characterized by X-ray diffraction, FTIR spectroscopy and in vitro dissolution tests in order to select the most suitable polymer for future investigations. The results showed that Eudragit® EPO was the most promising polymer for ellagic acid solid dispersions development because its extrudates allowed to obtain a solution supersaturated in ellagic acid that was stable for at least 90 min. Moreover, the resulting apparent solubility was 20 times higher than the actual solubility of ellagic acid. The extrudates also showed a high dissolution rate of ellagic acid (96.25% in 15 min), compared to the corresponding physical mixture (6.52% in 15 min) or the pure drug (1.56% in 15 min). Furthermore, increasing the loading rate of ellagic acid up to 12% in extrudates based on this polymer did not negatively influence its release profile through dissolution tests.
Collapse
Affiliation(s)
- Isaïe Nyamba
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Université de Liège, 4000 Liège (Belgium); Laboratory of Drug Development, Center of training, research and expertise in pharmaceutical sciences (CFOREM), Doctoral School of Sciences and Health, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03 (Burkina Faso).
| | - Olivier Jennotte
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Université de Liège, 4000 Liège (Belgium)
| | - Charles B Sombie
- Laboratory of Drug Development, Center of training, research and expertise in pharmaceutical sciences (CFOREM), Doctoral School of Sciences and Health, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03 (Burkina Faso)
| | - Anna Lechanteur
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Université de Liège, 4000 Liège (Belgium)
| | - Pierre-Yves Sacre
- Laboratory of Pharmaceutical Analytical Chemistry, Department of Pharmacy, Center for Interdisciplinary Research on Medicines (CIRM), University of Liege, 4000 Liege, Belgium
| | - Abdoulaye Djande
- Department of Chemistry, Laboratory of Molecular Chemistry and Materials, Research Team: Organic Chemistry and Phytochemistry, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03 (Burkina Faso)
| | - Rasmané Semde
- Laboratory of Drug Development, Center of training, research and expertise in pharmaceutical sciences (CFOREM), Doctoral School of Sciences and Health, Université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou 03 (Burkina Faso)
| | - Brigitte Evrard
- Laboratory of Pharmaceutical Technology and Biopharmacy, Center for Interdisciplinary Research on Medicines (CIRM), Université de Liège, 4000 Liège (Belgium)
| |
Collapse
|
6
|
Jiang J, Lu A, Ma X, Ouyang D, Williams RO. The applications of machine learning to predict the forming of chemically stable amorphous solid dispersions prepared by hot-melt extrusion. Int J Pharm X 2023; 5:100164. [PMID: 36798832 PMCID: PMC9925947 DOI: 10.1016/j.ijpx.2023.100164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Accepted: 01/17/2023] [Indexed: 01/24/2023] Open
Abstract
Amorphous solid dispersion (ASD) is one of the most important strategies to improve the solubility and dissolution rate of poorly water-soluble drugs. As a widely used technique to prepare ASDs, hot-melt extrusion (HME) provides various benefits, including a solvent-free process, continuous manufacturing, and efficient mixing compared to solvent-based methods, such as spray drying. Energy input, consisting of thermal and specific mechanical energy, should be carefully controlled during the HME process to prevent chemical degradation and residual crystallinity. However, a conventional ASD development process uses a trial-and-error approach, which is laborious and time-consuming. In this study, we have successfully built multiple machine learning (ML) models to predict the amorphization of crystalline drug formulations and the chemical stability of subsequent ASDs prepared by the HME process. We utilized 760 formulations containing 49 active pharmaceutical ingredients (APIs) and multiple types of excipients. By evaluating the built ML models, we found that ECFP-LightGBM was the best model to predict amorphization with an accuracy of 92.8%. Furthermore, ECFP-XGBoost was the best in estimating chemical stability with an accuracy of 96.0%. In addition, the feature importance analyses based on SHapley Additive exPlanations (SHAP) and information gain (IG) revealed that several processing parameters and material attributes (i.e., drug loading, polymer ratio, drug's Extended-connectivity fingerprints (ECFP) fingerprints, and polymer's properties) are critical for achieving accurate predictions for the selected models. Moreover, important API's substructures related to amorphization and chemical stability were determined, and the results are largely consistent with the literature. In conclusion, we established the ML models to predict formation of chemically stable ASDs and identify the critical attributes during HME processing. Importantly, the developed ML methodology has the potential to facilitate the product development of ASDs manufactured by HME with a much reduced human workload.
Collapse
Affiliation(s)
- Junhuang Jiang
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA
| | - Anqi Lu
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA
| | - Xiangyu Ma
- Global Investment Research, Goldman Sachs, NY 10282, USA
| | - Defang Ouyang
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences (ICMS), University of Macau, 999078, Macau
| | - Robert O. Williams
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA,Corresponding author.
| |
Collapse
|
7
|
Huang S, Venables DS, Lawrence SE. Pharmaceutical Salts of Piroxicam and Meloxicam with Organic Counterions. CRYSTAL GROWTH & DESIGN 2022; 22:6504-6520. [PMID: 36817751 PMCID: PMC9933440 DOI: 10.1021/acs.cgd.2c00722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Revised: 10/13/2022] [Indexed: 06/18/2023]
Abstract
Piroxicam (PRM) and meloxicam (MEL) are two nonsteroidal anti-inflammatory drugs, belonging to the Biopharmaceutics Classification System Class II drugs. In this study, six novel pharmaceutical salts of PRM and MEL with three basic organic counterions, that is, 4-aminopyridine (4AP), 4-dimethylaminopyridine (4DMP), and piperazine (PPZ), were prepared by both slurrying and slow evaporation. These salts were characterized by single-crystal and powder X-ray diffraction, thermal analysis, and Fourier transform infrared spectroscopy. All six salts, especially MEL-4DMP and MEL-4AP, showed a significantly improved apparent solubility and dissolution rate in sodium phosphate solution compared with the pure APIs. Notably, PRM-4AP and PRM-4DMP salts exhibited enhanced fluorescence, and the PRM-PPZ salt showed weaker fluorescence compared with that of pure PRM due to different luminescence mechanisms.
Collapse
Affiliation(s)
- Shan Huang
- School
of Chemistry, Analytical and Biological Chemistry Research Facility,
Synthesis and Solid State Pharmaceutical Centre, University College Cork, Cork T12 K8AF, Ireland
| | - Dean S. Venables
- School
of Chemistry and Environmental Research Institute, University College Cork, Cork T12 K8AF, Ireland
| | - Simon E. Lawrence
- School
of Chemistry, Analytical and Biological Chemistry Research Facility,
Synthesis and Solid State Pharmaceutical Centre, University College Cork, Cork T12 K8AF, Ireland
| |
Collapse
|
8
|
Emam MF, El-Ashmawy AA, Mursi NM, Emara LH. Optimization of Meloxicam Solid Dispersion Formulations for Dissolution Enhancement and Storage Stability Using 3 3 Full Factorial Design Based on Response Surface Methodology. AAPS PharmSciTech 2022; 23:248. [PMID: 36056201 DOI: 10.1208/s12249-022-02394-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Accepted: 08/09/2022] [Indexed: 11/30/2022] Open
Abstract
This study aimed to formulate and optimize solid-dispersion of meloxicam (MX) employing response-surface-methodology (RSM). RSM allowed identification of the main effects and interactions between studied factors on MX dissolution and acceleration of the optimization process. 33 full factorial design with 27 different formulations was proposed. Effects of drug loading percentage (A), carriers' ratio (B), method of preparation (C), and their interactions on percent MX dissolved after 10 and 30 min (Q10min & Q30min) from fresh and stored samples were studied in distilled water. The considered levels were 2.5%, 5.0%, and 7.5% (factor A), three ratios of Soluplus®/Poloxamer-407 (factor B). Physical mixture (PM), fusion method (FM), and hot-melt-extrusion (HME) were considered factor (C). Stability studies were carried out for 3 months under stress conditions. The proposed optimization design was validated by 3-extra checkpoints formulations. The optimized formulation was selected via numerical optimization and investigated by DSC, XRD, PLM, and in vitro dissolution study. Results showed that HME technique gave the highest MX dissolution rate compared to other techniques (FM & PM). At constant level of factor (C), the amount of MX dissolved increased by decreasing MX loading and increasing Soluplus in carriers' ratio. Actual responses of the optimized formulation were in close consistency with predicted data. Amorphous form of MX in the optimized formulation was proved by DSC, XRD, and PLM. Selected factors and their levels of the optimization design were significantly valuable for demonstrating and adapting the expected formulation characteristics for rapid dissolution of MX (Q10min= 89.09%) from fresh and stored samples.
Collapse
Affiliation(s)
- Maha F Emam
- Industrial Pharmacy Laboratory, Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre (Affiliation ID: 10014618), 33 EL Bohouth St. (former EL Tahrir St.), Dokki, P.O.12622, Giza, Egypt.
| | - Ahmed A El-Ashmawy
- Industrial Pharmacy Laboratory, Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre (Affiliation ID: 10014618), 33 EL Bohouth St. (former EL Tahrir St.), Dokki, P.O.12622, Giza, Egypt
| | - Nadia M Mursi
- Department of Pharmaceutics, Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt
| | - Laila H Emara
- Industrial Pharmacy Laboratory, Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre (Affiliation ID: 10014618), 33 EL Bohouth St. (former EL Tahrir St.), Dokki, P.O.12622, Giza, Egypt
| |
Collapse
|
9
|
Kayser K, Monschke M, Wagner KG. ASD Formation Prior to Material Characterization as Key Parameter for Accurate Measurements and Subsequent Process Simulation for Hot-Melt Extrusion. AAPS PharmSciTech 2022; 23:176. [PMID: 35750968 DOI: 10.1208/s12249-022-02331-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2022] [Accepted: 06/09/2022] [Indexed: 11/30/2022] Open
Abstract
Process simulation facilitates scale-up of hot-melt extrusion (HME) and enhances proper understanding of the underlying critical process parameters. However, performing numeric simulations requires profound knowledge of the employed materials' properties. For example, an accurate description of the compounds' melt rheology is paramount for proper simulations. Hence, sample preparation needs to be optimized to yield results as predictive as possible. To identify the optimal preparation method for small amplitude oscillatory shear (SAOS) rheological measurements, binary mixtures of hydroxypropylmethylcellulose acetate succinate or methacrylic acid ethyl acrylate copolymer (Eudragit L100-55) together with the model drugs celecoxib and ketoconazole were prepared. The physical powder mixtures were introduced into the SAOS as a compressed tablet or a disk prepared via vacuum compression molding (VCM). Simulations with the derived parameters were conducted and compared to lab-scale extrusion trials. VCM was identified as the ideal preparation method resulting in the highest similarity between simulated and experimental values, while simulation based on conventional powder-based methods insufficiently described the HME process.
Collapse
Affiliation(s)
- Kevin Kayser
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Gerhard-Domagk-Str. 3, 53121, Bonn, Germany
| | - Marius Monschke
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Gerhard-Domagk-Str. 3, 53121, Bonn, Germany
| | - Karl G Wagner
- Department of Pharmaceutical Technology and Biopharmaceutics, University of Bonn, Gerhard-Domagk-Str. 3, 53121, Bonn, Germany.
| |
Collapse
|
10
|
Liu T, Kaur N, Chen B, Phillips B, Chang SY, Yang F, Bi V, Durig T, Zhang F. Physicochemical Changes and Chemical Degradation of Gliclazide during Twin-Screw Melt Granulation. Int J Pharm 2022; 619:121702. [PMID: 35341908 DOI: 10.1016/j.ijpharm.2022.121702] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Revised: 03/20/2022] [Accepted: 03/22/2022] [Indexed: 10/18/2022]
Abstract
Using a miscible model formulation consisting of 80% gliclazide (GLZ) and 20% hydroxypropyl cellulose, we investigate how the twin-screw melt granulation process affects the chemical stability and process-induced physicochemical changes of the drug. No degradation was observed in the conveying section that leads to kneading element. Approximately 1/3 of the GLZ degradant was generated at the kneading section, while the remaining 2/3 was generated in the conveying section post-kneading and during cooling outside the barrel. A strong correlation was observed between the overall degradation and the temperature of the granules at the barrel exit. In the kneading section, the degradant content correlates best with the specific mechanical energy. With higher specific mechanical energies, the size of the GLZ crystals was reduced further, resulting in more surface defects. In the section post-kneading element, GLZ degradation correlates best with the granule temperature measured at the kneading section. This knowledge of drug degradation during twin-screw melt granulation can be used to develop processing strategies to maintain drug stability during and post processing.
Collapse
Affiliation(s)
- Tongzhou Liu
- Division of Molecular Pharmaceutics and Drug Delivery, the University of Texas at Austin, Austin, TX
| | - Navpreet Kaur
- Department of Pharmaceutics, University of Minnesota, Minneapolis, MN
| | - Beibei Chen
- Division of Molecular Pharmaceutics and Drug Delivery, the University of Texas at Austin, Austin, TX
| | - Brian Phillips
- Pharmaceutical Technology, Ashland Specialty Ingredients, Wilmington, DE
| | - Shao-Yu Chang
- Pharmaceutical Technology, Ashland Specialty Ingredients, Wilmington, DE
| | - Fengyuan Yang
- Pharmaceutical Technology, Ashland Specialty Ingredients, Wilmington, DE
| | - Vivian Bi
- Pharmaceutical Technology, Ashland Specialty Ingredients, Wilmington, DE
| | - Thomas Durig
- Pharmaceutical Technology, Ashland Specialty Ingredients, Wilmington, DE
| | - Feng Zhang
- Division of Molecular Pharmaceutics and Drug Delivery, the University of Texas at Austin, Austin, TX.
| |
Collapse
|
11
|
de Assis JMC, Barbosa EJ, Bezzon VDN, Lourenço FR, Carvalho FMS, Matos JR, Araci Bou-Chacra N, Benmore CJ, Byrn SR, Costa FN, de Araujo GLB. Hot-melt extrudability of amorphous solid dispersions of flubendazole-copovidone: An exploratory study of the effect of drug loading and the balance of adjuvants on extrudability and dissolution. Int J Pharm 2022; 614:121456. [PMID: 35017024 DOI: 10.1016/j.ijpharm.2022.121456] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2021] [Revised: 12/13/2021] [Accepted: 01/05/2022] [Indexed: 12/18/2022]
Abstract
The FDA-approved anthelmintic flubendazole has shown potential to be repositioned to treat cancer and dry macular degeneration; however, its poor water solubility limits its use. Amorphous solid dispersions may overcome this challenge, but the balance of excipients may impact the preparation method and drug release. The purpose of this study was to evaluate the influence of adjuvants and drug loading on the development of an amorphous solid dispersion of flubendazole-copovidone by hot-melt extrusion. The drug, copovidone, and adjuvants (magnesium stearate and hydroxypropyl cellulose) mixtures were statistically designed, and the process was performed in a twin-screw extruder. The study showed that flubendazole and copovidone mixtures were highly extrudable, except when drug loading was high (>40%). Furthermore, magnesium stearate positively impacted the extrusion and was more effective than hydroxypropyl cellulose. The extruded materials were evaluated by modulated differential scanning calorimetry and X-ray powder diffraction, obtaining positive amorphization and physical stability results. Pair distribution function analysis indicated the presence of drug-rich domains with medium-range order structure and no evidence of polymer-drug interaction. All extrudates presented faster dissolution (HCl, pH 1.2) than pure flubendazole, and both adjuvants had a notable influence on the dissolution rate. In conclusion, hot-melt extrusion may be a viable option to obtain stable flubendazole:copovidone amorphous dispersions.
Collapse
Affiliation(s)
- João M C de Assis
- Department of Pharmacy, School of Pharmaceutical Sciences, University of São Paulo (USP), São Paulo 05508-000, SP, Brazil
| | - Eduardo J Barbosa
- Department of Pharmacy, School of Pharmaceutical Sciences, University of São Paulo (USP), São Paulo 05508-000, SP, Brazil
| | - Vinícius D N Bezzon
- Center for Natural Sciences and Humanities (CCNH), Federal University of ABC (UFABC), Santo André 09210580, SP, Brazil
| | - Felipe R Lourenço
- Department of Pharmacy, School of Pharmaceutical Sciences, University of São Paulo (USP), São Paulo 05508-000, SP, Brazil
| | - Flavio M S Carvalho
- Geosciences Institute, Department of Mineralogy and Geotectonics, University of São Paulo (USP), São Paulo 05508-08, SP, Brazil
| | - J R Matos
- Department of Fundamental Chemistry, Institute of Chemistry, University of São Paulo (USP), São Paulo 05508-000, SP, Brazil.
| | - Nadia Araci Bou-Chacra
- Department of Pharmacy, School of Pharmaceutical Sciences, University of São Paulo (USP), São Paulo 05508-000, SP, Brazil
| | - Chris J Benmore
- X-ray Science Division, Advanced Photon Source, Argonne National Laboratory, IL, 60439, United States
| | - Stephen R Byrn
- Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, IN 47906, United States
| | - Fanny N Costa
- Diamond Light Source, Harwell Science and Innovation Campus, Didcot, Oxfordshire OX110DE, United Kingdom
| | - Gabriel L B de Araujo
- Department of Pharmacy, School of Pharmaceutical Sciences, University of São Paulo (USP), São Paulo 05508-000, SP, Brazil.
| |
Collapse
|
12
|
Thompson SA, Davis DA, Moon C, Williams RO. Increasing Drug Loading of Weakly Acidic Telmisartan in Amorphous Solid Dispersions through pH Modification during Hot-Melt Extrusion. Mol Pharm 2022; 19:318-331. [PMID: 34846902 DOI: 10.1021/acs.molpharmaceut.1c00805] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Oral drug therapy requiring large quantities of active pharmaceutical ingredients (APIs) can cause a substantial pill burden, which can increase nonadherence and worsen healthcare outcomes. Maximizing the drug loading of APIs in oral dosage forms is essential to reduce pill burden. This can be challenging for poorly water-soluble APIs without compromising performance. We show a promising strategy for maximizing the drug loading of pH-dependent APIs in amorphous solid dispersions (ASDs) produced by hot-melt extrusion (HME) without compromising their dissolution performance. We examine potential increases in the drug loading (w/w) of telmisartan in ASDs by incorporating bases to modify pH during HME. Telmisartan is a weakly acidic, poorly water-soluble API with pH-dependent solubility. It is practically insoluble at physiological pH, but its solubility increases exponentially at pH values above 10. Telmisartan was extruded with the polymer Soluplus and various bases. With no base, the maximum drug loading achieved by extrusion was only 5% before crystalline telmisartan was detected. Including a strong, water-soluble base (NaOH or KOH) increased the maximum amorphous drug loading to 50%. These results indicate that telmisartan has pH-dependent solubility in a molten polymer, similar to that in an aqueous solution. We also examine the stability of Soluplus when extruded with a strong base, using solid-state nuclear magnetic resonance (ssNMR) to determine that NaOH (but not KOH) causes degradation by hydrolysis. Supersaturation was maintained for at least 20 h during dissolution testing of a 50% telmisartan ASD in biorelevant media.
Collapse
Affiliation(s)
- Stephen A Thompson
- Division of Molecular Pharmaceutics and Drug Delivery, The University of Texas at Austin College of Pharmacy, Austin, Texas 78712, United States
| | - Daniel A Davis
- Division of Molecular Pharmaceutics and Drug Delivery, The University of Texas at Austin College of Pharmacy, Austin, Texas 78712, United States
| | - Chaeho Moon
- Division of Molecular Pharmaceutics and Drug Delivery, The University of Texas at Austin College of Pharmacy, Austin, Texas 78712, United States
| | - Robert O Williams
- Division of Molecular Pharmaceutics and Drug Delivery, The University of Texas at Austin College of Pharmacy, Austin, Texas 78712, United States
| |
Collapse
|
13
|
Anane-Adjei AB, Jacobs E, Nash SC, Askin S, Soundararajan R, Kyobula M, Booth J, Campbell A. Amorphous Solid Dispersions: Utilization and Challenges in Preclinical Drug Development within AstraZeneca. Int J Pharm 2021; 614:121387. [PMID: 34933082 DOI: 10.1016/j.ijpharm.2021.121387] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Revised: 11/23/2021] [Accepted: 12/12/2021] [Indexed: 01/04/2023]
Abstract
The poor aqueous solubility of many active pharmaceutical ingredients (APIs) dominates much of the early drug development portfolio and poses a major challenge in pharmaceutical development. Polymer-based amorphous solid dispersions (ASDs) are becoming increasingly common and offer a promising formulation strategy to tackle the solubility and oral absorption issues of these APIs. This review discusses the design, manufacture, and utilisation of ASD formulations in preclinical drug development, with a key focus on the pre-formulation assessments and workflows employed at AstraZeneca.
Collapse
Affiliation(s)
- Akosua B Anane-Adjei
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D AstraZeneca, Granta Park, Cambridge, CB21 6GH, UK
| | - Esther Jacobs
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D AstraZeneca, Granta Park, Cambridge, CB21 6GH, UK
| | - Samuel C Nash
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D AstraZeneca, Granta Park, Cambridge, CB21 6GH, UK
| | - Sean Askin
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D AstraZeneca, Granta Park, Cambridge, CB21 6GH, UK
| | - Ramesh Soundararajan
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D AstraZeneca, Granta Park, Cambridge, CB21 6GH, UK
| | - Mary Kyobula
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D AstraZeneca, Granta Park, Cambridge, CB21 6GH, UK
| | - Jonathan Booth
- Pharmaceutical Technology & Development, AstraZeneca, Charter Way, Macclesfield, SK10 2NA, UK
| | - Andrew Campbell
- Advanced Drug Delivery, Pharmaceutical Sciences, R&D AstraZeneca, Granta Park, Cambridge, CB21 6GH, UK.
| |
Collapse
|
14
|
Lee JH, Park C, Weon KY, Kang CY, Lee BJ, Park JB. Improved Bioavailability of Poorly Water-Soluble Drug by Targeting Increased Absorption through Solubility Enhancement and Precipitation Inhibition. Pharmaceuticals (Basel) 2021; 14:ph14121255. [PMID: 34959655 PMCID: PMC8707685 DOI: 10.3390/ph14121255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Revised: 11/27/2021] [Accepted: 11/29/2021] [Indexed: 11/16/2022] Open
Abstract
Itraconazole (ITZ) is a class II drug according to the biopharmaceutical classification system. Its solubility is pH 3-dependent, and it is poorly water-soluble. Its pKa is 3.7, which makes it a weak base drug. The aim of this study was to prepare solid dispersion (SD) pellets to enhance the release of ITZ into the gastrointestinal environment using hot-melt extrusion (HME) technology and a pelletizer. The pellets were then filled into capsules and evaluated in vitro and in vivo. The ITZ changed from a crystalline state to an amorphous state during the HME process, as determined using DSC and PXRD. In addition, its release into the gastrointestinal tract was enhanced, as was the level of ITZ recrystallization, which was lower than the marketed drug (Sporanox®), as assessed using an in vitro method. In the in vivo study that was carried out in rats, the AUC0-48h of the commercial formulation, Sporanox®, was 1073.9 ± 314.7 ng·h·mL-1, and the bioavailability of the SD pellet (2969.7 ± 720.6 ng·h·mL-1) was three-fold higher than that of Sporanox® (*** p < 0.001). The results of the in vivo test in beagle dogs revealed that the AUC0-24h of the SD-1 pellet (which was designed to enhance drug release into gastric fluids) was 3.37 ± 3.28 μg·h·mL-1 and that of the SD-2 pellet (which was designed to enhance drug release in intestinal fluids) was 7.50 ± 4.50 μg·h·mL-1. The AUC of the SD-2 pellet was 2.2 times higher than that of the SD-1 pellet. Based on pharmacokinetic data, ITZ would exist in a supersaturated state in the area of drug absorption. These results indicated that the absorption area is critical for improving the bioavailability of ITZ. Consequently, the bioavailability of ITZ could be improved by inhibiting precipitation in the absorption area.
Collapse
Affiliation(s)
- Ju-Hyun Lee
- College of Pharmacy, Sahmyook University, Seoul 01795, Korea; (J.-H.L.); (C.-Y.K.)
| | - Chulhun Park
- Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2E1, Canada;
| | - Kwon-Yeon Weon
- College of Pharmacy, Catholic University of Daegu, Gyeongsan-si 38430, Korea;
| | - Chin-Yang Kang
- College of Pharmacy, Sahmyook University, Seoul 01795, Korea; (J.-H.L.); (C.-Y.K.)
| | - Beom-Jin Lee
- College of Pharmacy, Ajou University, Suwon 16499, Korea;
| | - Jun-Bom Park
- College of Pharmacy, Sahmyook University, Seoul 01795, Korea; (J.-H.L.); (C.-Y.K.)
- Bioavailability Control Lab, Sahmyook University, Seoul 01795, Korea
- Correspondence: ; Tel.: +82-2-3399-1624
| |
Collapse
|
15
|
Zhou H, Wang Y, Li S, Lu M. Improving chemical stability of resveratrol in hot melt extrusion based on formation of eutectic with nicotinamide. Int J Pharm 2021; 607:121042. [PMID: 34450224 DOI: 10.1016/j.ijpharm.2021.121042] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2021] [Revised: 07/29/2021] [Accepted: 08/21/2021] [Indexed: 11/26/2022]
Abstract
Hot melt extrusion (HME) is a technique applied in the preparation of pharmaceutical amorphous solid dispersions (ASD). Notably it is important to prevent thermal degradation of heat-sensitive drugs during HME. In this study, we present a new strategy to improve chemical stability of pharmaceutical compounds during HME through the formation of eutectics with small molecules. Resveratrol (RES) was selected as the model compound because it is a heat-liable natural product with a very high melting point of 267 °C. When heated at its melting point for 3 min, it degrades by 40%. RES can co-crystallize with nicotinamide (NIC) in solution, however, it can only form a eutectic with NIC during heating. HPMCAS was selected as the polymer matrix and the drug loading of RES was fixed as 20% (weight ratio). The lowest extrusion temperature that can result to RES-HPMCAS ASD is 215 °C. At this temperature, RES shows 7.36% degradation during extrusion. Replacement of 21.4% HPMCAS with NIC decreased the melting temperature of NIC and thus lowered the minimal extrusion temperature to 155 °C. This effectively prevented thermal degradation of RES without negatively affecting non-sink dissolution. The only extra cost for this method is stricter storage conditions (low temperature and low humidity) due to the low glass transition temperature of NIC. Similar strategy may be applied to other heat-liable drugs in similar ways. This study demonstrates the use of eutectic formation for preventing thermal degradation of drug during extrusion of ASD.
Collapse
Affiliation(s)
- Huanyue Zhou
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
| | - Yu Wang
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
| | - Shuting Li
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
| | - Ming Lu
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
| |
Collapse
|
16
|
Machine Learning for Process Monitoring and Control of Hot-Melt Extrusion: Current State of the Art and Future Directions. Pharmaceutics 2021; 13:pharmaceutics13091432. [PMID: 34575508 PMCID: PMC8466632 DOI: 10.3390/pharmaceutics13091432] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2021] [Revised: 08/26/2021] [Accepted: 09/06/2021] [Indexed: 01/11/2023] Open
Abstract
In the last few decades, hot-melt extrusion (HME) has emerged as a rapidly growing technology in the pharmaceutical industry, due to its various advantages over other fabrication routes for drug delivery systems. After the introduction of the ‘quality by design’ (QbD) approach by the Food and Drug Administration (FDA), many research studies have focused on implementing process analytical technology (PAT), including near-infrared (NIR), Raman, and UV–Vis, coupled with various machine learning algorithms, to monitor and control the HME process in real time. This review gives a comprehensive overview of the application of machine learning algorithms for HME processes, with a focus on pharmaceutical HME applications. The main current challenges in the application of machine learning algorithms for pharmaceutical processes are discussed, with potential future directions for the industry.
Collapse
|
17
|
Lagan C, Huckle JE, Katz JM, Khorsand B, Daurio D, Andrews GP, Chung J, Alvarez-Nunez F. Solvent-Assisted Hot Melt Extrusion of a Thermally Labile, High Melting Point Compound. AAPS PharmSciTech 2021; 22:235. [PMID: 34498147 DOI: 10.1208/s12249-021-02122-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Accepted: 08/18/2021] [Indexed: 11/30/2022] Open
Abstract
Molecular dispersions are a highly effective method of increasing bioavailability for a poorly soluble active pharmaceutical ingredient (API) and can be prepared on a large scale by hot melt extrusion (HME). Processing thermally labile active pharmaceutical ingredients (APIs) via HME is generally more difficult, with operating temperatures limited to below that of the API melting point. API melting is considered essential to facilitate the formation of a fully homogeneous amorphous system. Processing below the melting point renders the system much more susceptible to residual crystalline content; hence, HME is not suitable for APIs which degrade upon melting. In the following work, meloxicam (MEL) was used as a model API, possessing properties of high melting temperature and thermal lability. In this proof of concept work, a modified HME method, termed solvent-assisted HME, was used to overcome this issue and prepare an amorphous solid dispersion using HME, wherein a solvent was incorporated in the formulation blend during extrusion and removed post-processing. Formulations containing 10%wt meloxicam (MEL) and 90%wt polyvinylpyrrolidone vinyl acetate (PVPVA) copolymer were extruded using a twin-screw extruder at temperatures below the melting point of MEL. Dimethylformamide (DMF) solvent was added directly into the extruder barrel through a liquid addition port, resulting in extrudate products having a higher conversion of API to the amorphous form. The incorporation of solvent allowed a significant reduction in processing temperatures due to its increased mobility, while also driving the conversion of the API to its amorphous form. The solvent was successfully reduced through a secondary drying step using a vacuum oven. This advancement has demonstrated the potential for thermally labile APIs to be processed via HME expanding the applications of this technology.
Collapse
|
18
|
|
19
|
Thompson SA, Williams RO. Specific mechanical energy - An essential parameter in the processing of amorphous solid dispersions. Adv Drug Deliv Rev 2021; 173:374-393. [PMID: 33781785 DOI: 10.1016/j.addr.2021.03.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 02/04/2021] [Accepted: 03/08/2021] [Indexed: 10/21/2022]
Abstract
Specific mechanical energy (SME) is a frequently overlooked but essential parameter of hot-melt extrusion (HME). It can determine whether an amorphous solid dispersion (ASD) can be successfully processed. A minimum combination of thermal input and SME is required to convert a crystalline active pharmaceutical product (API) into its amorphous form. A maximum combination is allowed before it or the carrier polymer chemically degrades. This has important implications on design space. SME input during HME provides information on the totality of the effect of various independent processing parameters such as screw speed, feed rate, and complex viscosity. If only these independent processing parameters are considered separately instead of SME, then important information would be lost regarding the interaction of these parameters and their ability to affect ASD formulation. A complete understanding of the HME process requires an analysis of SME. This paper provides a review of SME use in the pharmaceutical processing of ASDs, the importance of SME in terms of a variety of formulation qualities, and novel future uses of SME. Theoretical background is discussed, along with the relative importance of thermal and mechanical input on various nonsolvent ASD processing methods.
Collapse
|
20
|
Emam MF, Taha NF, Mursi NM, Emara LH. Preparation, characterization and in-Vitro/in-Vivo evaluation of meloxicam extruded pellets with enhanced bioavailability and stability. Drug Dev Ind Pharm 2020; 47:163-175. [PMID: 33297790 DOI: 10.1080/03639045.2020.1862175] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
OBJECTIVE The present study involved enhancement of Meloxicam (MX) oral absorption for rapid onset of therapeutic action. A challenging approach using hot-melt-extrusion technique (HME) for production of stable novel preparation of MX pellets was successfully proposed. METHODS Manipulating HME processing parameters (barrel-temperatures and screw-speed) and proper polymer(s) selection (Soluplus, a combination of Soluplus/Poloxamar and Polyethylene Glycol 6000) were the main strategies involved for productive extrusion of MX. Evaluation of MX solid-state (TGA, DSC and PLM), absolute percent crystallinity, in-vitro dissolution (in acidic/aqueous pHs), and stability testing in accelerated conditions up to 6-months as well as a long-term shelf for 36-months were performed. A comparative bioavailability study of selected MX-Pellets was carried-out against the innovator product (Mobic®) in 6 healthy volunteers under fed-conditions. RESULTS TGA, DSC and PLM analyses proved the dispersion of MX in amorphous-state within polymeric matrix by HME. MX/Soluplus pellets exhibited the lowest crystallinity % and best dissolution performance among other polymers in both pHs. In addition, presence of Soluplus safeguards final pellets stability under different storage conditions. MX rate of absorption (Tmax) from Soluplus-based pellets attained a value of 45 min, which was 6-times faster than Mobic® (4.5 hr). CONCLUSION A promising oral MX formula prepared by HME was successfully developed with a rapid onset of analgesic action (Tmax of 45 mins; almost 2-times faster than reported intramuscular injection), hence appropriate in the early relief of pain associated with rheumatoid arthritis and osteoarthritis. Moreover, the proposed formula was physico-chemically stable up to 36 months of shelf-life storage.
Collapse
Affiliation(s)
- Maha F Emam
- Industrial Pharmacy Laboratory, Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Giza, Egypt
| | - Nesrin F Taha
- Industrial Pharmacy Laboratory, Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Giza, Egypt
| | - Nadia M Mursi
- Department of Pharmaceutics, Faculty of Pharmacy, Cairo University, Cairo, Egypt
| | - Laila H Emara
- Industrial Pharmacy Laboratory, Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Centre, Giza, Egypt
| |
Collapse
|
21
|
Hanada M, Jermain SV, Thompson SA, Furuta H, Fukuda M, Williams RO. Ternary Amorphous Solid Dispersions Containing a High-Viscosity Polymer and Mesoporous Silica Enhance Dissolution Performance†. Mol Pharm 2020; 18:198-213. [PMID: 33291881 DOI: 10.1021/acs.molpharmaceut.0c00811] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The aim of this study was to evaluate the benefits of a ternary amorphous solid dispersion (ASD) that was designed as an immediate-release tablet with a high drug load (e.g., 40% w/w) to produce heightened maintenance of drug supersaturation during dissolution testing, which will be henceforth referred to as the "maintenance ability". Ternary ASD granules were produced by hot melt extrusion (HME) and were comprised of itraconazole (ITZ) 50%, hypromellose (HPMC) 20%, and mesoporous silica (XDP) 30%, where amorphous ITZ incorporated into HPMC was efficiently absorbed in XDP pores. The ternary ASD granules containing a high-viscosity HPMC (AF4M) produced a significantly heightened maintenance ability of drug supersaturation in neutral pH dissolution media in which crystalline ITZ solubility is below 1 μg/mL. The final tablet formulation contained 80% w/w of the ASD granules (40% w/w ITZ), had an acceptable size, and exhibited both sufficient tablet hardness and disintegration. The dissolution behavior of the ternary ASD tablet exhibited a supersaturation maintenance ability similar to that of the ASD granules. Under neutral conditions, the ternary ASD tablet showed immediate and higher ITZ release compared with the binary ASD tablets, and this phenomenon could be explained by the difference in ITZ/AF4M particle size in the tablet. In high-resolution scanning electron microscopy (SEM), it was observed that ITZ and AF4M in the ternary formulation could easily form nano-sized particles (<1 μm) during the absorption process into/onto XDP pores prepared by HME, which contributed to the immediate ITZ release from the ternary ASD tablet under neutral pH conditions. Therefore, the ternary ASD containing high-viscosity HPMC and mesoporous silica prepared by HME made it possible to design a high ASD content, small-size tablet with an ideal dissolution profile in biorelevant media, and we expect that this technology can be applied for continuous HME ASD manufacturing.
Collapse
Affiliation(s)
- Masataka Hanada
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, United States.,CMC Research Laboratory, Watarase Research Center, Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan
| | - Scott V Jermain
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, United States.,Formulation and Process Development, Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States
| | - Stephen A Thompson
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, United States
| | - Hirosuke Furuta
- CMC Research Laboratory, Watarase Research Center, Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan
| | - Mamoru Fukuda
- CMC Research Laboratory, Watarase Research Center, Kyorin Pharmaceutical Co., Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan
| | - Robert O Williams
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, United States
| |
Collapse
|
22
|
Kittikunakorn N, Paul S, Koleng JJ, Liu T, Cook R, Yang F, Bi V, Durig T, Sun CC, Kumar A, Zhang F. How Does the Dissimilarity of Screw Geometry Impact Twin-screw Melt Granulation? Eur J Pharm Sci 2020; 157:105645. [PMID: 33207275 DOI: 10.1016/j.ejps.2020.105645] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2020] [Revised: 10/19/2020] [Accepted: 11/10/2020] [Indexed: 11/19/2022]
Abstract
Using a model formulation of 80% gabapentin and 20% hydroxypropyl cellulose (KlucelTM), we investigate how differences in the geometry of mixing elements in the Leistritz Nano-16 and Micro-18 extruders affect granulation mechanisms and the properties of the resulting granules. Two extruders, Leistritz Nano-16 and Micro-18, commonly used in development and manufacturing, respectively, were used. The kneading blocks of the Nano-16 extruder are less efficient in dispersive mixing than the kneading blocks of the Micro-18 due to the thinner discs (2.5 mm wide) of the Nano-16. Therefore, our model formulation could be granulated only under a higher degree of fill (DF) by enhancing the axial compaction and heating of the barrel. In contrast, the thicker (5 mm wide) kneading blocks of the Micro-18 extruder provide efficient dispersive mixing that enables granulation without axial compaction and barrel heating. The higher specific mechanical energy (SME) achieved at higher screw speeds and lower feed rates led to more granulation. Because of the difference in granulation mechanisms between the two extruders, critical processing parameters also differed. Tabletability and degradant content of granules correlated positively with DF for the Nano-16 but with SME for the Micro-18 extruder.
Collapse
Affiliation(s)
- Nada Kittikunakorn
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, the University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, USA
| | - Shubhajit Paul
- Department of Pharmaceutics, University of Minnesota, 308 SE Harvard St, Minneapolis, MN 55455, USA
| | - John J Koleng
- Division of Chemical Engineering, School of Engineering, the University of Texas at Austin, 200 E Dean Keeton St, Austin, TX 78712, USA
| | - Tongzhou Liu
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, the University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, USA
| | - Rachel Cook
- Department of Materials Science and Engineering, Missouri University of Science and Technology, Rolla, MO 65409, USA
| | - Fengyuan Yang
- Pharmaceutical Technology, Ashland Specialty Ingredients, Wilmington, DE
| | - Vivian Bi
- Pharmaceutical Technology, Ashland Specialty Ingredients, Wilmington, DE
| | - Thomas Durig
- Pharmaceutical Technology, Ashland Specialty Ingredients, Wilmington, DE
| | - Changquan Calvin Sun
- Department of Pharmaceutics, University of Minnesota, 308 SE Harvard St, Minneapolis, MN 55455, USA
| | - Aditya Kumar
- Department of Materials Science and Engineering, Missouri University of Science and Technology, Rolla, MO 65409, USA
| | - Feng Zhang
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, the University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, USA.
| |
Collapse
|
23
|
Tan DK, Davis DA, Miller DA, Williams RO, Nokhodchi A. Innovations in Thermal Processing: Hot-Melt Extrusion and KinetiSol® Dispersing. AAPS PharmSciTech 2020; 21:312. [PMID: 33161479 PMCID: PMC7649167 DOI: 10.1208/s12249-020-01854-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2020] [Accepted: 10/14/2020] [Indexed: 12/23/2022] Open
Abstract
Thermal processing has gained much interest in the pharmaceutical industry, particularly for the enhancement of solubility, bioavailability, and dissolution of active pharmaceutical ingredients (APIs) with poor aqueous solubility. Formulation scientists have developed various techniques which may include physical and chemical modifications to achieve solubility enhancement. One of the most commonly used methods for solubility enhancement is through the use of amorphous solid dispersions (ASDs). Examples of commercialized ASDs include Kaletra®, Kalydeco®, and Onmel®. Various technologies produce ASDs; some of the approaches, such as spray-drying, solvent evaporation, and lyophilization, involve the use of solvents, whereas thermal approaches often do not require solvents. Processes that do not require solvents are usually preferred, as some solvents may induce toxicity due to residual solvents and are often considered to be damaging to the environment. The purpose of this review is to provide an update on recent innovations reported for using hot-melt extrusion and KinetiSol® Dispersing technologies to formulate poorly water-soluble APIs in amorphous solid dispersions. We will address development challenges for poorly water-soluble APIs and how these two processes meet these challenges.
Collapse
Affiliation(s)
- Deck Khong Tan
- Pharmaceutics Research Laboratory, Arundel Building, School of Life Sciences, University of Sussex, Brighton, BN1 9QJ, UK
| | - Daniel A Davis
- College of Pharmacy, The University of Texas at Austin, Austin, Texas, 78712, USA
| | - Dave A Miller
- DisperSol Technologies, LLC, 111 W. Cooperative Way, Building 3, Suite 300, Georgetown, Texas, 78626, USA
| | - Robert O Williams
- College of Pharmacy, The University of Texas at Austin, Austin, Texas, 78712, USA.
| | - Ali Nokhodchi
- Pharmaceutics Research Laboratory, Arundel Building, School of Life Sciences, University of Sussex, Brighton, BN1 9QJ, UK.
| |
Collapse
|
24
|
Application and limitations of thermogravimetric analysis to delineate the hot melt extrusion chemical stability processing window. Int J Pharm 2020; 590:119916. [DOI: 10.1016/j.ijpharm.2020.119916] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 09/18/2020] [Accepted: 09/20/2020] [Indexed: 11/17/2022]
|
25
|
Characterization of ternary amorphous solid dispersion containing hypromellose phthalate and erythritol prepared by hot melt extrusion using melting point depression. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2020.101797] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
26
|
Kittikunakorn N, Liu T, Zhang F. Twin-screw melt granulation: Current progress and challenges. Int J Pharm 2020; 588:119670. [PMID: 32739382 DOI: 10.1016/j.ijpharm.2020.119670] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Revised: 07/03/2020] [Accepted: 07/15/2020] [Indexed: 02/06/2023]
Abstract
Twin-screw melt granulation (TSMG) is a new alternative method for granulation that offers several advantages over wet and dry granulation methods. TSMG has rapidly gained interest over recent years in the pharmaceutical industry. Since it is an inherently continuous process with controlled temperature and shear history, TSMG produces products with more consistent quality than the batch process. Several studies have investigated how various formulation and processing parameters influence granulation behavior and granule properties; however, there are still challenges that require a better mechanistic understanding. This review summarizes the current progress of TSMG while highlighting how various formulation and process parameters affect the physicochemical properties of granules. The challenges related to the process-induced physicochemical changes of drug substances are also discussed.
Collapse
Affiliation(s)
- Nada Kittikunakorn
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409, University Avenue, Austin, TX 78712, United States
| | - Tongzhou Liu
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409, University Avenue, Austin, TX 78712, United States
| | - Feng Zhang
- Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, 2409, University Avenue, Austin, TX 78712, United States.
| |
Collapse
|
27
|
Influence of Carbamazepine Dihydrate on the Preparation of Amorphous Solid Dispersions by Hot Melt Extrusion. Pharmaceutics 2020; 12:pharmaceutics12040379. [PMID: 32326114 PMCID: PMC7238004 DOI: 10.3390/pharmaceutics12040379] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2020] [Revised: 04/03/2020] [Accepted: 04/15/2020] [Indexed: 11/24/2022] Open
Abstract
Amorphous solid dispersions (ASDs) are commonly used in the pharmaceutical industry to improve the dissolution and bioavailability of poorly water-soluble drugs. Hot melt extrusion (HME) has been employed to prepare ASD based products. However, due to the narrow processing window of HME, ASDs are normally obtained with high processing temperatures and mechanical stress. Interestingly, one-third of pharmaceutical compounds reportedly exist in hydrate forms. In this study, we selected carbamazepine (CBZ) dihydrate to investigate its solid-state changes during the dehydration process and the impact of the dehydration on the preparation of CBZ ASDs using a Leistritz micro-18 extruder. Various characterization techniques were used to study the dehydration kinetics of CBZ dihydrate under different conditions. We designed the extrusion runs and demonstrated that: 1) the dehydration of CBZ dihydrate resulted in a disordered state of the drug molecule; 2) the resulted higher energy state CBZ facilitated the drug solubilization and mixing with the polymer matrix during the HME process, which significantly decreased the required extrusion temperature from 140 to 60 °C for CBZ ASDs manufacturing compared to directly processing anhydrous crystalline CBZ. This work illustrated that the proper utilization of drug hydrates can significantly improve the processability of HME for preparing ASDs.
Collapse
|
28
|
Gala U, Miller D, Williams RO. Improved Dissolution and Pharmacokinetics of Abiraterone through KinetiSol ® Enabled Amorphous Solid Dispersions. Pharmaceutics 2020; 12:pharmaceutics12040357. [PMID: 32295245 PMCID: PMC7238130 DOI: 10.3390/pharmaceutics12040357] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Revised: 04/02/2020] [Accepted: 04/10/2020] [Indexed: 01/11/2023] Open
Abstract
Abiraterone is a poorly water-soluble drug. It has a high melting point and limited solubility in organic solvents, making it difficult to formulate as an amorphous solid dispersion (ASD) with conventional technologies. KinetiSol® is a high-energy, fusion-based, solvent-free technology that can produce ASDs. The aim of this study was to evaluate the application of KinetiSol to make abiraterone ASDs. We developed binary KinetiSol ASDs (KSDs) using both polymers and oligomers. For the first time, we reported that KinetiSol can process hydroxypropyl-β-cyclodextrin (HPBCD), a low molecular-weight oligomer. Upon X-ray diffractometry and modulated differential scanning calorimetry analysis, we found the KSDs to be amorphous. In vitro dissolution analysis revealed that maximum abiraterone dissolution enhancement was achieved using a HPBCD binary KSD. However, the KSD showed significant abiraterone precipitation in fasted state simulated intestinal fluid (FaSSIF) media. Hence, hypromellose acetate succinate (HPMCAS126G) was selected as an abiraterone precipitation inhibitor and an optimized ternary KSD was developed. A pharmacokinetic study revealed that HPBCD based binary and ternary KSDs enhanced abiraterone bioavailability by 12.4-fold and 13.8-fold, respectively, compared to a generic abiraterone acetate tablet. Thus, this study is the first to demonstrate the successful production of an abiraterone ASD that exhibited enhanced dissolution and bioavailability.
Collapse
Affiliation(s)
- Urvi Gala
- Molecular Pharmaceutics and Drug Delivery Division, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Austin, TX 78712, USA;
- DisperSol Technologies LLC., 111 W. Cooperative Way, Building 3, Suite 300, Georgetown, TX 78626, USA;
| | - Dave Miller
- DisperSol Technologies LLC., 111 W. Cooperative Way, Building 3, Suite 300, Georgetown, TX 78626, USA;
| | - Robert O. Williams
- Molecular Pharmaceutics and Drug Delivery Division, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Austin, TX 78712, USA;
- Correspondence:
| |
Collapse
|
29
|
Fan W, Zhang X, Zhu W, Di L. The Preparation of Curcumin Sustained-Release Solid Dispersion by Hot-Melt Extrusion—Ⅱ. Optimization of Preparation Process and Evaluation In Vitro and In Vivo. J Pharm Sci 2020; 109:1253-1260. [DOI: 10.1016/j.xphs.2019.11.020] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Revised: 11/03/2019] [Accepted: 11/21/2019] [Indexed: 11/29/2022]
|
30
|
Simões MF, Pinto RM, Simões S. Hot-melt extrusion in the pharmaceutical industry: toward filing a new drug application. Drug Discov Today 2019; 24:1749-1768. [DOI: 10.1016/j.drudis.2019.05.013] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Revised: 03/29/2019] [Accepted: 05/17/2019] [Indexed: 01/30/2023]
|
31
|
Fan W, Zhu W, Zhang X, Xu Y, Di L. Application of the combination of ball-milling and hot-melt extrusion in the development of an amorphous solid dispersion of a poorly water-soluble drug with high melting point. RSC Adv 2019; 9:22263-22273. [PMID: 35519487 PMCID: PMC9066646 DOI: 10.1039/c9ra00810a] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Accepted: 07/02/2019] [Indexed: 11/21/2022] Open
Abstract
The aim of the study was to develop an amorphous solid dispersion of a poorly water-soluble drug with high melting point by ball milling and hot melt extrusion as a co-processing method. Solid dispersion systems were prepared by ball milling-hot melt extrusion and then compared with those prepared with hot melt extrusion. The effects of three process parameters in the co-processing method, namely, barrel temperature, screw speed, and cooling rate, were systematically studied. The physical state of prepared solid dispersion was characterized by differential scanning calorimetry, X-ray diffraction, Fourier transform infrared spectroscopy, scanning electron microscopy, phase solubility, and dissolution study. The Resveratrol-Eudragit® EPO system exhibited good miscibility and significant dissolution enhancement. Resveratrol in the amorphous solid dispersion existed in an amorphous state and had molecular interactions with Eudragit® EPO. Stability studies showed no apparent difference in the physical state of the solid dispersion after 6 months. In conclusion, combining ball milling with hot melt extrusion is a promising method for preparing the amorphous solid dispersion of a poorly water-soluble drug with high melting point.
Collapse
Affiliation(s)
- Wenling Fan
- Laboratory of Pharmaceutical Engineering, College of Pharmacy, Nanjing University of Chinese Medicine Nanjing 210023 China
- Institute of Jiangsu Engineering Research Center for Efficient Delivery System of Traditional Chinese Medicine Nanjing 210023 China
- Jiangsu Collaborative Innovation Center of Chinese Medicine Resources Industrialization Nanjing 210023 China
| | - Wenjing Zhu
- Laboratory of Pharmaceutical Engineering, College of Pharmacy, Nanjing University of Chinese Medicine Nanjing 210023 China
- Institute of Jiangsu Engineering Research Center for Efficient Delivery System of Traditional Chinese Medicine Nanjing 210023 China
| | - Xinyi Zhang
- Laboratory of Pharmaceutical Engineering, College of Pharmacy, Nanjing University of Chinese Medicine Nanjing 210023 China
- Institute of Jiangsu Engineering Research Center for Efficient Delivery System of Traditional Chinese Medicine Nanjing 210023 China
| | - Yan Xu
- Laboratory of Pharmaceutical Engineering, College of Pharmacy, Nanjing University of Chinese Medicine Nanjing 210023 China
- Institute of Jiangsu Engineering Research Center for Efficient Delivery System of Traditional Chinese Medicine Nanjing 210023 China
| | - Liuqing Di
- Laboratory of Pharmaceutical Engineering, College of Pharmacy, Nanjing University of Chinese Medicine Nanjing 210023 China
- Institute of Jiangsu Engineering Research Center for Efficient Delivery System of Traditional Chinese Medicine Nanjing 210023 China
| |
Collapse
|
32
|
Wesholowski J, Hoppe K, Nickel K, Muehlenfeld C, Thommes M. Scale-Up of pharmaceutical Hot-Melt-Extrusion: Process optimization and transfer. Eur J Pharm Biopharm 2019; 142:396-404. [PMID: 31295504 DOI: 10.1016/j.ejpb.2019.07.009] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Revised: 07/01/2019] [Accepted: 07/06/2019] [Indexed: 11/26/2022]
Abstract
Hot-Melt-Extrusion on Twin-Screw-Extruders has been established as a standard processing technique for pharmaceutical products. A major challenge is the transfer from a lab to a production level, since the combination of several unit operations within one apparatus leads to complex conditions for such a continuous manufacturing process. Here the residence time distribution is a crucial measure, which reflects the different mechanisms, e.g. dissolution, mixing or degradation, during processing. In the first part of a Scale-Up study, a methodology for the optimization of an extrusion process with respect to the load and throughput is presented. The developed concept was applied for different extruder scales in order to compare the identified processing windows. A deviation of the dominant material heating mechanisms was observed for the different scales, while the constraints for the transfer of a process to a different scale by the developed optimization concept is demonstrated. Finally, a sufficient operating point on a reference extruder is identified and in the second part of this study, different concepts from literature are applied for the transfer of this Hot-Melt-Extrusion process to two larger scales. The focus of the investigations was on the impact of the different approaches on the residence time distribution and the comparison. The determined results revealed a change of the most sufficient approach for the two different extruder sizes. The impact on the location in the time domain and form of the distribution are discussed and additionally evaluated by the fit to a RTD-model. In conclusion, the ratio of the applied energy for transport to mixing is identified as valuable addition in this context.
Collapse
Affiliation(s)
- Jens Wesholowski
- Laboratory of Solids Process Engineering, TU Dortmund University, Dortmund, Germany
| | - Kevin Hoppe
- Laboratory of Solids Process Engineering, TU Dortmund University, Dortmund, Germany
| | | | | | - Markus Thommes
- Laboratory of Solids Process Engineering, TU Dortmund University, Dortmund, Germany.
| |
Collapse
|
33
|
Li Y, Lu M, Wu C. PVP VA64 as a novel release-modifier for sustained-release mini-matrices prepared via hot melt extrusion. Drug Deliv Transl Res 2019; 8:1670-1678. [PMID: 29127610 DOI: 10.1007/s13346-017-0437-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The purpose of this study was to explore poly(vinylpyrrolidone-co-vinyl acetate) (PVP VA64) as a novel release-modifier to tailor the drug release from ethylcellulose (EC)-based mini-matrices prepared via hot melt extrusion (HME). Quetiapine fumarate (QF) was selected as model drug. QF/EC/PVP VA64 mini-matrices were extruded with 30% drug loading. The physical state of QF in extruded mini-matrices was characterized using differential scanning calorimetry, X-ray powder diffraction, and confocal Raman microscopy. The release-controlled ability of PVP VA64 was investigated and compared with that of xanthan gum, crospovidone, and low-substituted hydroxypropylcellulose. The influences of PVP VA64 content and processing temperature on QF release behavior and mechanism were also studied. The results indicated QF dispersed as the crystalline state in all mini-matrices. The release of QF from EC was very slow as only 4% QF was released in 24 h. PVP VA64 exhibited the best ability to enhance the drug release as compared with other three release-modifiers. The drug release increased to 50-100% in 24 h with the addition of 20-40% PVP VA64. Increasing processing temperature slightly slowed down the drug release by decreasing free volume and pore size. The release kinetics showed good fit with the Ritger-Peppas model. The values of release exponent (n) increased as PVP VA64 is added (0.14 for pure EC, 0.41 for 20% PVP VA64, and 0.61 for 40% PVP VA64), revealing that the addition of PVP VA64 enhanced the erosion mechanism. This work presented a new polymer blend system of EC with PVP VA64 for sustained-release prepared via HME.
Collapse
Affiliation(s)
- Yongcheng Li
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
| | - Ming Lu
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
| | - Chuanbin Wu
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China
| |
Collapse
|
34
|
Huang D, Xie Z, Rao Q, Liamas E, Pan P, Guan S, Zhang ZJ, Lu M, Li Q. Hot melt extrusion of heat-sensitive and high melting point drug: Inhibit the recrystallization of the prepared amorphous drug during extrusion to improve the bioavailability. Int J Pharm 2019; 565:316-324. [DOI: 10.1016/j.ijpharm.2019.04.064] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2018] [Revised: 04/04/2019] [Accepted: 04/21/2019] [Indexed: 11/16/2022]
|
35
|
Kittikunakorn N, Sun CC, Zhang F. Effect of screw profile and processing conditions on physical transformation and chemical degradation of gabapentin during twin-screw melt granulation. Eur J Pharm Sci 2019; 131:243-253. [DOI: 10.1016/j.ejps.2019.02.024] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Revised: 02/12/2019] [Accepted: 02/16/2019] [Indexed: 11/26/2022]
|
36
|
Investigation of Drug–Polymer Miscibility and Solubilization on Meloxicam Binary Solid Dispersion. J Pharm Innov 2019. [DOI: 10.1007/s12247-019-09378-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
37
|
Jermain SV, Miller D, Spangenberg A, Lu X, Moon C, Su Y, Williams RO. Homogeneity of amorphous solid dispersions - an example with KinetiSol ®. Drug Dev Ind Pharm 2019; 45:724-735. [PMID: 30653376 DOI: 10.1080/03639045.2019.1569037] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
KinetiSol® is a high-shear, fusion-based technology capable of producing stable amorphous solid dispersions (ASDs) without the assistance of solvent. KinetiSol® has proven successful with multiple challenging BCS class II and IV drugs, where drug properties like thermal instability or lack of appreciable solubility in volatile solvents make hot melt extrusion or spray drying unfeasible. However, there is a necessity to characterize the ASDs like those made by the KinetiSol® process, in order to better understand whether KinetiSol® is capable of homogeneously dispersing drug throughout a carrier in a short (<40 s) processing time. Our study utilized the high melting point, BCS class II drug, meloxicam, in order to evaluate the degree of homogeneity of 1, 5, and 10% w/w KinetiSol®-processed samples. Powder blend homogeneity and content uniformity were evaluated, and all samples demonstrated a meloxicam concentration % relative standard deviation of ≤2.0%. SEM/EDS was utilized to map elemental distribution of the processed samples, which confirmed KinetiSol®-processed materials were homogeneous at a 25 µm2 area. Utilizing Raman spectroscopy, we were able to verify the amorphous content of the processed samples. Finally, we utilized ssNMR 1 H spin-lattice relaxation measurement to evaluate the molecular miscibility of meloxicam with the polymer at 1% w/w drug load, for the first time, and determined the processed sample was highly miscible at ∼200 nm scale. In conclusion, we determined the KinetiSol® process is capable of producing ASDs that are homogeneously and molecularly well-dispersed drug-in-polymer at drug concentrations as low as 1% w/w.
Collapse
Affiliation(s)
- Scott V Jermain
- a Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin , Austin , TX , USA
| | - Dave Miller
- b DisperSol Technologies, LLC , Georgetown , TX , USA
| | | | - Xingyu Lu
- c Merck Research Laboratories (MRLs), Merck & Co., Inc. , Kenilworth , NJ , USA
| | - Chaeho Moon
- a Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin , Austin , TX , USA
| | - Yongchao Su
- a Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin , Austin , TX , USA.,c Merck Research Laboratories (MRLs), Merck & Co., Inc. , Kenilworth , NJ , USA
| | - Robert O Williams
- a Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin , Austin , TX , USA
| |
Collapse
|
38
|
Melt-based screening method with improved predictability regarding polymer selection for amorphous solid dispersions. Eur J Pharm Sci 2018; 124:339-348. [DOI: 10.1016/j.ejps.2018.08.035] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Revised: 08/23/2018] [Accepted: 08/25/2018] [Indexed: 11/15/2022]
|
39
|
Moseson DE, Taylor LS. The application of temperature-composition phase diagrams for hot melt extrusion processing of amorphous solid dispersions to prevent residual crystallinity. Int J Pharm 2018; 553:454-466. [PMID: 30393199 DOI: 10.1016/j.ijpharm.2018.10.055] [Citation(s) in RCA: 61] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2018] [Revised: 10/22/2018] [Accepted: 10/23/2018] [Indexed: 11/26/2022]
Abstract
Hot melt extrusion (HME) can be used to produce amorphous solid dispersions (ASDs) at temperatures below the drug's melting point if the drug and polymer exhibit melting point depression. However, the risk of residual crystallinity becomes significant. The purpose of this study was to apply the temperature-composition phase diagram to the HME process, correlating process conditions to ASD residual crystallinity, and identifying the formulation critical temperature, which defines the theoretical minimum processing temperature. The phase diagram of indomethacin (IDM) and polyvinylpyrrolidone/vinyl acetate copolymer (PVPVA) was generated using melting point depression measurements coupled with Flory-Huggins theory. Extrudates were manufactured above, at, and below the formulation critical temperature (Tc) as identified from the phase diagram, with a range of residence times, and characterized for crystallinity. Below the Tc, a fully amorphous sample could not be prepared. Above Tc, sufficient residence time led to amorphous samples. A processing operating design space diagram with three regimes was generated to correlate temperature and residence time factors with process outcome. In conclusion, phase diagrams provide a rational basis for designing hot melt extrusion processes of amorphous solid dispersions to minimize residual crystalline content, delineating the minimum processing temperature based on thermodynamic considerations.
Collapse
Affiliation(s)
- Dana E Moseson
- Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, United States
| | - Lynne S Taylor
- Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette, IN 47907, United States.
| |
Collapse
|
40
|
Haser A, Haight B, Berghaus A, Machado A, Martin C, Zhang F. Scale-Up and In-line Monitoring During Continuous Melt Extrusion of an Amorphous Solid Dispersion. AAPS PharmSciTech 2018; 19:2818-2827. [PMID: 30255473 DOI: 10.1208/s12249-018-1162-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2018] [Accepted: 08/22/2018] [Indexed: 11/30/2022] Open
Abstract
Chemical degradation of drug substances remains a major drawback of extrusion. Larger-scale extrusion equipment has advantages over smaller equipment due to deeper flight elements and added flexibility in terms of screw design, unit operations, and residence time. In a previous study, we extruded a meloxicam-copovidone amorphous solid dispersion (ASD) on a Nano-16 extruder and achieved 96.7% purity. The purpose of this study is to introduce a strategy for scaling the process to an extruder with dissimilar geometry and to investigate the impact on the purity of the ASD. The formulation previously optimized on the Nano-16, 10:90 meloxicam and copovidone, was used for scale-up. Our approach to scale-up to the ZSE-18, utilized specific mechanical energy input and degree of fill from the Nano-16. Vacuum was added to prevent hydrolysis of meloxicam. Downstream feeding and micronization of meloxicam were introduced to reduce the residence time. In-line monitoring of the solubilization of meloxicam was monitored with a UV probe positioned at the die. We were able to achieve the same purity of meloxicam with the Micro-18 as we achieved with Nano-16. When process conditions alone were not sufficient, meglumine was added to further stabilize meloxicam. In addition to the chemical stability advantage that meglumine provided, we also observed solubility enhancement which allowed for an increase in drug loading to 20% while maintaining 100% purity.
Collapse
|
41
|
Hanada M, Jermain SV, Lu X, Su Y, Williams RO. Predicting physical stability of ternary amorphous solid dispersions using specific mechanical energy in a hot melt extrusion process. Int J Pharm 2018; 548:571-585. [DOI: 10.1016/j.ijpharm.2018.07.029] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Revised: 07/09/2018] [Accepted: 07/09/2018] [Indexed: 11/15/2022]
|
42
|
Censi R, Gigliobianco MR, Casadidio C, Di Martino P. Hot Melt Extrusion: Highlighting Physicochemical Factors to Be Investigated While Designing and Optimizing a Hot Melt Extrusion Process. Pharmaceutics 2018; 10:E89. [PMID: 29997332 PMCID: PMC6160992 DOI: 10.3390/pharmaceutics10030089] [Citation(s) in RCA: 75] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Revised: 06/22/2018] [Accepted: 07/09/2018] [Indexed: 12/15/2022] Open
Abstract
Hot-melt extrusion (HME) is a well-accepted and extensively studied method for preparing numerous types of drug delivery systems and dosage forms. It offers several advantages: no solvents are required, it is easy to scale up and employ on the industrial level, and, in particular, it offers the possibility of improving drug bioavailability. HME involves the mixing of a drug with one or more excipients, in general polymers and even plasticizers, which can melt, often forming a solid dispersion of the drug in the polymer. The molten mass is extruded and cooled, giving rise to a solid material with designed properties. This process, which can be realized using different kinds of special equipment, may involve modifications in the drug physicochemical properties, such as chemical, thermal and mechanical characteristics thus affecting the drug physicochemical stability and bioavailability. During process optimization, the evaluation of the drug solid state and stability is thus of paramount importance to guarantee stable drug properties for the duration of the drug product shelf life. This manuscript reviews the most important physicochemical factors that should be investigated while designing and optimizing a hot melt extrusion process, and by extension, during the different pre-formulation, formulation and process, and post-formulation phases. It offers a comprehensive evaluation of the chemical and thermal stability of extrudates, the solid physical state of extrudates, possible drug-polymer interactions, the miscibility/solubility of the drug-polymer system, the rheological properties of extrudates, the physicomechanical properties of films produced by hot melt extrusion, and drug particle dissolution from extrudates. It draws upon the last ten years of research, extending inquiry as broadly as possible.
Collapse
Affiliation(s)
- Roberta Censi
- School of Pharmacy, University of Camerino, Via S. Agostino, 62032 Camerino, Italy.
| | | | - Cristina Casadidio
- School of Pharmacy, University of Camerino, Via S. Agostino, 62032 Camerino, Italy.
| | - Piera Di Martino
- School of Pharmacy, University of Camerino, Via S. Agostino, 62032 Camerino, Italy.
| |
Collapse
|
43
|
Ellenberger DJ, Miller DA, Williams RO. Expanding the Application and Formulation Space of Amorphous Solid Dispersions with KinetiSol®: a Review. AAPS PharmSciTech 2018; 19:1933-1956. [PMID: 29846889 DOI: 10.1208/s12249-018-1007-2] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2017] [Accepted: 03/28/2018] [Indexed: 01/19/2023] Open
Abstract
Due to the high number of poorly soluble drugs in the development pipeline, novel processes for delivery of these challenging molecules are increasingly in demand. One such emerging method is KinetiSol, which utilizes high shear to produce amorphous solid dispersions. The process has been shown to be amenable to difficult to process active pharmaceutical ingredients with high melting points, poor organic solubility, or sensitivity to heat degradation. Additionally, the process enables classes of polymers not conventionally processable due to their high molecular weight and/or poor organic solubility. Beyond these advantages, the KinetiSol process shows promise with other applications, such as the production of amorphous mucoadhesive dispersions for delivery of compounds that would also benefit from permeability enhancement.
Collapse
|
44
|
Evans RC, Kyeremateng SO, Asmus L, Degenhardt M, Rosenberg J, Wagner KG. Development and Performance of a Highly Sensitive Model Formulation Based on Torasemide to Enhance Hot-Melt Extrusion Process Understanding and Process Development. AAPS PharmSciTech 2018; 19:1592-1605. [PMID: 29488197 DOI: 10.1208/s12249-018-0970-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Accepted: 02/05/2018] [Indexed: 11/30/2022] Open
Abstract
The aim of this work was to investigate the use of torasemide as a highly sensitive indicator substance and to develop a formulation thereof for establishing quantitative relationships between hot-melt extrusion process conditions and critical quality attributes (CQAs). Using solid-state characterization techniques and a 10 mm lab-scale co-rotating twin-screw extruder, we studied torasemide in a Soluplus® (SOL)-polyethylene glycol 1500 (PEG 1500) matrix, and developed and characterized a formulation which was used as a process indicator to study thermal- and hydrolysis-induced degradation, as well as residual crystallinity. We found that torasemide first dissolved into the matrix and then degraded. Based on this mechanism, extrudates with measurable levels of degradation and residual crystallinity were produced, depending strongly on the main barrel and die temperature and residence time applied. In addition, we found that 10% w/w PEG 1500 as plasticizer resulted in the widest operating space with the widest range of measurable residual crystallinity and degradant levels. Torasemide as an indicator substance behaves like a challenging-to-process API, only with higher sensitivity and more pronounced effects, e.g., degradation and residual crystallinity. Application of a model formulation containing torasemide will enhance the understanding of the dynamic environment inside an extruder and elucidate the cumulative thermal and hydrolysis effects of the extrusion process. The use of such a formulation will also facilitate rational process development and scaling by establishing clear links between process conditions and CQAs.
Collapse
|
45
|
Haser A, Zhang F. New Strategies for Improving the Development and Performance of Amorphous Solid Dispersions. AAPS PharmSciTech 2018; 19:978-990. [PMID: 29340977 DOI: 10.1208/s12249-018-0953-z] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2017] [Accepted: 01/02/2018] [Indexed: 01/23/2023] Open
Abstract
The understanding of amorphous solid dispersions has grown significantly in the past decade. This is evident from the number of approved commercial amorphous solid dispersion products. While amorphous formulation is considered an enabling technology, it has become the norm for formulating poorly soluble compounds. Despite this success, improvements can still be made that enable early development formulation decisions, to develop a rationale for selecting a manufacturing process, to overcome degradation and phase separation during processing, to help achieve physical stability during storage, and to optimize dissolution behavior. The purpose of this literature review is to present recently reported strategies for improving the development and performance of ASDs. The benefits and limitations of each strategy as well as recent relevant case studies will be presented in this review. The strategies are presented from three different aspects: (a) prediction techniques that enable formulation decisions, (b) manufacturing considerations that help produce physically and chemically stable ASDs, and
Collapse
|
46
|
Haser A, Cao T, Lubach JW, Zhang F. In Situ Salt Formation during Melt Extrusion for Improved Chemical Stability and Dissolution Performance of a Meloxicam–Copovidone Amorphous Solid Dispersion. Mol Pharm 2018; 15:1226-1237. [DOI: 10.1021/acs.molpharmaceut.7b01057] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Abbe Haser
- Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, United States
| | - Tu Cao
- Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, United States
| | - Joseph W. Lubach
- Genentech, 1 DNA Way, South San Francisco, California 94080, United States
| | - Feng Zhang
- Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, A1920, Austin, Texas 78712, United States
| |
Collapse
|
47
|
Melt extrusion with poorly soluble drugs - An integrated review. Int J Pharm 2017; 535:68-85. [PMID: 29102700 DOI: 10.1016/j.ijpharm.2017.10.056] [Citation(s) in RCA: 143] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Revised: 10/29/2017] [Accepted: 10/31/2017] [Indexed: 11/20/2022]
Abstract
Over the last few decades, hot melt extrusion (HME) has emerged as a successful technology for a broad spectrum of applications in the pharmaceutical industry. As indicated by multiple publications and patents, HME is mainly used for the enhancement of solubility and bioavailability of poorly soluble drugs. This review is focused on the recent reports on the solubility enhancement via HME and provides an update for the manufacturing/scaling up aspects of melt extrusion. In addition, drug characterization methods and dissolution studies are discussed. The application of process analytical technology (PAT) tools and use of HME as a continuous manufacturing process may shorten the drug development process; as a result, the latter is becoming the most widely utilized technique in the pharmaceutical industry. The advantages, disadvantages, and practical applications of various PAT tools such as near and mid-infrared, ultraviolet/visible, fluorescence, and Raman spectroscopies are summarized, and the characteristics of other techniques are briefly discussed. Overall, this review also provides an outline for the currently marketed products and analyzes the strengths, weaknesses, opportunities and threats of HME application in the pharmaceutical industry.
Collapse
|
48
|
Huang S, O'Donnell KP, Delpon de Vaux SM, O'Brien J, Stutzman J, Williams RO. Processing thermally labile drugs by hot-melt extrusion: The lesson with gliclazide. Eur J Pharm Biopharm 2017; 119:56-67. [PMID: 28583588 DOI: 10.1016/j.ejpb.2017.05.014] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2017] [Revised: 04/25/2017] [Accepted: 05/29/2017] [Indexed: 11/18/2022]
Abstract
The formation of molecularly dispersed amorphous solid dispersions by the hot-melt extrusion technique relies on the thermal and mechanical energy inputs, which can cause chemical degradation of drugs and polymeric carriers. Additionally, drug degradation may be exacerbated as drugs convert from a more stable crystalline form to a higher energy amorphous form. Therefore, it is imperative to study how drug degrades and evaluate methods to minimize drug degradation during the extrusion process. In this work, gliclazide was used as a model thermally labile drug for the degradation kinetics and process optimization studies. Preformulation studies were conducted using thermal analyses, and liquid chromatography-mass spectroscopy to identify drug degradation pathways and to determine initial extrusion conditions. Formulations containing 10% drug and 90% AFFINISOL™ HPMC HME 100LV were then extruded using a twin screw extruder, and the extrudates were characterized using X-ray powder diffraction, modulated dynamic scanning calorimetry, and potency testing to evaluate physicochemical properties. The energies of activation for both amorphous gliclazide, crystalline gliclazide, and gliclazide solution were calculated using the Arrhenius equation to further guide the extrusion optimization process. Preformulation studies identify two hydrolysis degradation pathways of gliclazide at elevated temperatures. The activation energy study indicates a significantly higher degradation rate for the amorphous gliclazide compared to the crystalline form. After optimization of the hot-melt extrusion process, including improved screw designs, machine setup, and processing conditions, gliclazide amorphous solid dispersion with ∼95% drug recovery was achieved. The ability to process thermally labile drugs and polymers using hot-melt extrusion will significantly expand the possible applications of this manufacturing process.
Collapse
Affiliation(s)
- Siyuan Huang
- Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Mail Stop A1920, Austin, TX, United States; Small Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States
| | - Kevin P O'Donnell
- The Dow Chemical Company, Dow Food, Pharma & Medical, Midland, MI, United States
| | - Sophie M Delpon de Vaux
- Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Mail Stop A1920, Austin, TX, United States
| | - John O'Brien
- The Dow Chemical Company, Analytical Sciences, Midland, MI, United States
| | - John Stutzman
- The Dow Chemical Company, Analytical Sciences, Midland, MI, United States
| | - Robert O Williams
- Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Mail Stop A1920, Austin, TX, United States.
| |
Collapse
|